ACADIA Pharmaceuticals (ACAD) News Today $17.23 +0.20 (+1.20%) As of 12:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Soleno jumps as analysts say US nod for rare disease drug transforms treatment optionsMarch 27 at 9:18 AM | reuters.comJames Kihara Sells 1,095 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMarch 27 at 6:16 AM | insidertrades.comEntryPoint Capital LLC Has $478,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)EntryPoint Capital LLC grew its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 137.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,022 shares of the biopharmaceutical company's stock after purchasiMarch 27 at 4:58 AM | marketbeat.comProficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Proficio Capital Partners LLC acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 14,827 shares of the biopharmaceutical company's stock, valued at approximately $272,000.March 27 at 3:17 AM | marketbeat.comFox Run Management L.L.C. Purchases Shares of 25,422 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Fox Run Management L.L.C. purchased a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 25,422 shares of the biopharmaceutMarch 26 at 4:32 AM | marketbeat.comIs ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street AnalystsMarch 25 at 6:11 PM | msn.comCannon Global Investment Management LLC Makes New $2.17 Million Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Cannon Global Investment Management LLC acquired a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 117,990 shares of the biopharmacMarch 25 at 6:04 AM | marketbeat.comAdvantage Alpha Capital Partners LP Sells 14,715 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Advantage Alpha Capital Partners LP decreased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 59.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,199 shares oMarch 25 at 5:05 AM | marketbeat.comWhat is Zacks Research's Estimate for ACAD Q1 Earnings?ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Zacks Research decreased their Q1 2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 18th. Zacks Research analyst A. Chakraborty now anticiMarch 21, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $24.00 Consensus Target Price from AnalystsMarch 21, 2025 | americanbankingnews.comZacks Research Brokers Reduce Earnings Estimates for ACADMarch 21, 2025 | americanbankingnews.comStoke Therapeutics reports Q EPS (18c), consensus (53c)March 19, 2025 | markets.businessinsider.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. decreased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 1.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,251,332 shareMarch 19, 2025 | marketbeat.comACADIA Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) was the target of some unusual options trading on Monday. Traders acquired 3,703 call options on the stock. This is an increase of 308% compared to the average daily volume of 908 call options.March 18, 2025 | marketbeat.comIs ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?March 18, 2025 | msn.comInvestors Purchase High Volume of Call Options on ACADIA Pharmaceuticals (NASDAQ:ACAD)March 18, 2025 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seventeen brokerages that are presently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a hold rating and nine have assigned a bMarch 18, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Bought by Victory Capital Management Inc.Victory Capital Management Inc. lifted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 66.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 162,125 shares of the biopharmaMarch 17, 2025 | marketbeat.comAcadia Pharmaceuticals issues new employee stock awardsMarch 16, 2025 | investing.comConnor Clark & Lunn Investment Management Ltd. Has $12.58 Million Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Connor Clark & Lunn Investment Management Ltd. trimmed its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 29.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 685,716 shares of the biopharmaceuticaMarch 16, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Bank of New York Mellon CorpBank of New York Mellon Corp decreased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 409,750 shares of the biopharmaceutical coMarch 16, 2025 | marketbeat.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 14, 2025 | businesswire.comACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progressMarch 14, 2025 | investing.comAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesMarch 13, 2025 | businesswire.comGreat Lakes Advisors LLC Takes Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Great Lakes Advisors LLC purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 540,013 shares of the biopharmaceutical company's stock, valueMarch 13, 2025 | marketbeat.comSaniona AB: Saniona and Boehringer Ingelheim extend research collaboration with one yearMarch 11, 2025 | finanznachrichten.deEx-San Diego biotech company VP admits to illegally selling $1.3M worth of sharesMarch 10, 2025 | msn.comEdgestream Partners L.P. Increases Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Edgestream Partners L.P. grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 20.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 264,390 shares of the biMarch 9, 2025 | marketbeat.comFormer San Diego Pharma VP pleads guilty to securities fraud for insider tradingMarch 8, 2025 | msn.comACADIA Pharmaceuticals' (ACAD) "Equal Weight" Rating Reiterated at Morgan StanleyMorgan Stanley reiterated an "equal weight" rating and set a $20.00 price target on shares of ACADIA Pharmaceuticals in a research note on Friday.March 8, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded at StockNews.comStockNews.com raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday.March 8, 2025 | marketbeat.comFormer Pharmaceutical Executive Pleads Guilty After $1.3M Gain from Insider TradingMarch 8, 2025 | msn.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Elizabeth A. Garofalo Sells 4,919 SharesACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. The trade was a 21.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 7, 2025 | marketbeat.comAcadia Pharmaceuticals Announces Positive DAFFODIL Study Data For DAYBUE In Rett SyndromeMarch 7, 2025 | nasdaq.comAcadia Pharmaceuticals assumed with an Equal Weight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Sells $89,673.37 in StockMarch 7, 2025 | insidertrades.comGuggenheim Remains a Buy on EyePoint Pharmaceuticals (EYPT)March 6, 2025 | markets.businessinsider.comClinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in MedMarch 6, 2025 | finance.yahoo.comFisher Asset Management LLC Purchases 132,906 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Fisher Asset Management LLC lifted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 68.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 327,505 shares of the biopharmaceutical compMarch 5, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Principal Financial Group Inc. grew its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 10.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 143,694 shares of the biopharmaceutical company's stock after buyMarch 5, 2025 | marketbeat.comAcadia Pharmaceuticals, Saniona announce results from ACP-711 cohortsMarch 3, 2025 | markets.businessinsider.comACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 3, 2025 | finance.yahoo.comAcadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 StudyMarch 3, 2025 | uk.finance.yahoo.comEquities Analysts Set Expectations for ACAD FY2025 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities research analysts at HC Wainwright dropped their FY2025 EPS estimates for shares of ACADIA Pharmaceuticals in a report issued on Thursday, February 27th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical compaMarch 3, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for ACAD Q1 Earnings?ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a report issued on Thursday, February 27th. Leerink Partnrs analyst M. Goodman expects that the biopharmMarch 3, 2025 | marketbeat.comAcadia Pharmaceuticals Ends FY2024 On Solid FootingMarch 2, 2025 | seekingalpha.comY Intercept Hong Kong Ltd Has $604,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Y Intercept Hong Kong Ltd cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 34.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,905 shares of the biopharmaceutical company's stock afterMarch 2, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded to "Hold" Rating by StockNews.comStockNews.com downgraded ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday.March 1, 2025 | marketbeat.comFY2025 EPS Estimates for ACAD Decreased by Cantor FitzgeraldACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research report issued on Thursday, February 27th. Cantor Fitzgerald analyst C. Duncan now expects that thMarch 1, 2025 | marketbeat.comBrokers Issue Forecasts for ACAD Q1 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for ACADIA Pharmaceuticals in a report released on Thursday, February 27th. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will post eMarch 1, 2025 | marketbeat.com Remove Ads Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Media Mentions By Week ACAD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACAD News Sentiment▼0.630.82▲Average Medical News Sentiment ACAD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACAD Articles This Week▼157▲ACAD Articles Average Week Remove Ads Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Viatris News Ascendis Pharma A/S News Vaxcyte News Qiagen News Roivant Sciences News Sarepta Therapeutics News Revolution Medicines News BridgeBio Pharma News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACAD) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
